Wide Ranks

GOVXW

GeoVax Labs, Inc.

0.1200

Top Statistics
Market Cap 0.0000 Forward PE 0.0000 Revenue Growth 0.00 %
Current Ratio 0.60 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins -1683.61 %
Balance Sheet
Total Cash 1 M Total Cash Per Share 0.2970 Total Debt 142292
Total Debt To Equity Current Ratio 0.60 Book Value Per Share 2.92
All Measures
Message Board Id finmb_12056751 Fax 678 384 7281 Return On Equity -3.62
City Smyrna Uuid c4aa58a8-4e19-3849-a2ba-e3aa8b9dadd7 Previous Close 0.1121
Book Value 2.92 Beta 3.11 Total Debt 142292
Volume 4125 Price To Book 0.0412 Fifty Two Week Low 0.1122
Total Cash Per Share 0.2970 Total Revenue 300677 Max Age 86400
Sand P52 Week Change 0.3133 Operating Margins -1683.61 % Net Income To Common -26915400
Trailing Peg Ratio None Total Cash 1 M Revenue Per Share 0.1430
Trailing PE 0.0000 Regular Market Previous Close 0.1121 Target Low Price 0.0000
Gmt Off Set Milliseconds -18000000 Open 0.1122 Free Cashflow -14219356
State GA Dividend Yield 0.00 % Return On Assets -1.34
Time Zone Short Name EST Day Low 0.1122 Address1 1900 Lake Park Drive
Target High Price 0.0000 Price Hint 4 Website https://www.geovax.com
Forward Eps 0.0000 Recommendation Key none Compensation As Of Epoch Date 1 B
Quick Ratio 29.10 % Is_sp_500 False Regular Market Day High 0.1206
Profit Margins 0.00 % Fifty Two Week High 0.1206 Day High 0.1206
Regular Market Open 0.1122 Industry Key biotechnology Earnings Growth 0.00 %
Revenue Growth 0.00 % Operating Cashflow -22998400 Currency USD
Time Zone Full Name America/New_York Is_nasdaq_100 False Market Cap 0.0000
Zip 30080 Quote Type EQUITY Industry Biotechnology
Long Name GeoVax Labs, Inc. Regular Market Day Low 0.1122 Current Price 0.1200
Address2 Suite 380 Financial Currency USD Current Ratio 0.60
Industry Disp Biotechnology Country United States Float Shares 5 M
Forward PE 0.0000 Regular Market Volume 4125 Ebitda -27155956
Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform.

It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.

The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine.

In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever.

It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.

S.

Department of Defense; Emory University; and the Burnet Institute.

GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.